3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
14
Gemcitabine
8
Docetaxel
7
Nivolumab
6
durvalumab
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
atezolizumab
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
sargramostim
3
aldesleukin
3
Specimen Handling
3
Radiotherapy
3
Paclitaxel
3
Ipilimumab
3
Fulvestrant
3
Cisplatin
3
Carboplatin
3
venetoclax
2
temsirolimus
2
talazoparib
2
spartalizumab
2
olaparib
2
liposomal doxorubicin
2
fludarabine phosphate
2
cabozantinib
2
budigalimab
2
avelumab
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
tinostamustine
×
Breast
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts